Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Halozyme posts record revenue in 2022, eyes growth opportunities

Halozyme's strong financial performance in 2022 and positive revenue guidance for 2023 reflect a robust growth trajectory.
While facing integration challenges from acquisitions and potential competition, the company's strategic priorities and market engagement remain strong.
Exploring new collaborations, advancing product development, and maintaining a competitive edge present key opportunities for Halozyme.
Overall, Halozyme's proactive approach to growth and market dynamics positions it well for future success in the biopharmaceutical industry.

Halozyme reports robust Q1 earnings, poised for continued growth

Halozyme's strong Q1 performance and robust pipeline position them for continued revenue growth and leadership in subcutaneous drug delivery.
Challenges include regulatory impacts and legal uncertainties, but opportunities in new agreements, partnerships, and investments offer avenues for future growth.
Overall, Halozyme's strategic focus on innovation and revenue diversification bodes well for their long-term success and financial stability.

Halozyme reports robust Q2 growth, eyes new partnerships for revenue

Halozyme's Q2 2023 earnings call showcased strong financial performance, innovative product developments, and a positive outlook for revenue growth. The company's focus on expanding partnerships, maintaining revenue durability, and strategic capital allocation positions it well for future success in the biopharmaceutical market.

Halozyme excels in Q3, raises guidance, eyes market expansion

Halozyme's Q3 performance reflects financial strength and operational resilience, supported by strategic partnerships and revenue growth.
The company's focus on shareholder value through accelerated buybacks and commitment to innovation positions them for sustained success.
While challenges like market competition exist, Halozyme's opportunities in market expansion and revenue growth paint a positive outlook for the future.

Halozyme posts record earnings, eyes strategic growth opportunities ahead

Halozyme's strong financial results and positive outlook for 2024 position the company for continued growth and value creation.
Addressing challenges around market adoption and reimbursement processes will be key to unlocking the full potential of subcutaneous products.
Strategic partnerships, new product launches, and a focus on shareholder value enhancement underscore Halozyme's commitment to sustainable growth.

Halozyme reports robust Q1 growth, navigates biosimilar challenges

Halozyme's Q1 2024 performance demonstrated strong financial growth driven by royalties and milestone payments, supported by operational achievements and strategic capital allocation.
While facing challenges such as biosimilar competition and partnership complexities, the company remains well-positioned to capitalize on opportunities in subcutaneous delivery preferences and market expansion.
Overall, Halozyme's focus on revenue diversification, partnership expansion, and operational excellence sets a positive trajectory for sustained growth and resilience in the biopharmaceutical sector.

Halozyme posts strong Q3 results, raises guidance amid growth opportunities

Halozyme Therapeutics reported a stellar Q3 performance with significant revenue growth and raised guidance across key financial metrics. The company's partnerships, product portfolio, and strong financial position underscore its growth potential and market resilience. Halozyme is well-positioned to capitalize on opportunities for expansion and innovation in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.74 per share a year ago.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

Halozyme Therapeutics obliterated second-quarter expectations late Tuesday, and the No. 1 biotech stock jumped in late action.

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.91 1 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus® SC in Europe and the UK and VYVGART® Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million, Representing YOY Growth of 13% - 22%, Adjusted EBITDA of $555 - $615 million, Representing YOY Growth of 30% - 44% and Non-GAAP Diluted EPS of $3.65 - $4.05, Representing YOY Growth of 32% - 46% SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2024, and provided an update on its recent corporate activities and outlook. "Our strong financial results reflect another quarter of double-digit royalty revenue, EBITDA and earnings growth.

HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Addus HomeCare

Atmos Energy

Leidos Hld

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics

United Therapeutics

Vertex Pharmaceuticals

The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.

3 Biotech Stocks on Track for 50% Returns (or More) by 2028

Axsome Therapeutics

Krystal Biotech

Moderna

Sarepta Therapeutics

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

5 Biotech Stocks to Bet On Bright Industry Prospects

SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m.

Halozyme to Report Second Quarter 2024 Financial and Operating Results

Amazon

Tenet Healthcare

A company capable of generating earnings well above its interest expense can withstand financial hardship. AMZN, HALO, THC and ATO are sound enough to meet financial obligations.

4 Stocks With Impressive Interest Coverage Ratio to Buy Now

Viking Therapeutics

The biotech sector possesses a significant predicted Compounding Annual Growth Rate (CAGR) of 14% between 2023 to 2032.  But the risks certainly match the rewards.

3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition

ADMA Biologics

CRISPR Therapeutics

Jazz Pharmaceuticals

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.

Add These 5 Hot Biotech Stocks In July

A recent patent approval for biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) resulted in raised 2024 guidance.

Big Money Eyes Halozyme for Strong Growth

Amgen

Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals.

3 Biotech Stocks to Buy Now: Q3 Edition

Haemonetics

Neurocrine Biosciences

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

Top Medical Stocks to Buy for Growth & Performance

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Biogen

Incyte

The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are pushing the boundaries of medicine and transforming patient care.

3 Highly Rated Biotech Stocks for Your July Buy List

Small biotech company Halozyme is behind some of the biggest names in medicine, including Johnson & Johnson's Darzalex and Roche's Tecentriq.

How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin

Novo Nordisk

With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful selection of industry leaders.

3 Breakout Biotech Stocks on Track to Double by 2032

OCREVUS® subcutaneous (SC) injection offers a new 10-minute administration with comparable efficacy and safety to intravenous (IV) infusion Provides an additional treatment option without the need for IV facilities, expanding accessibility for patients SAN DIEGO , June 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS® SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion.

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

VYVGART® Hytrulo  is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as a subcutaneous injection, approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) CIDP is the second FDA-approved indication for VYVGART® Hytrulo with ENHANZE® SAN DIEGO , June 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART® Hytrulo for CIDP is FDA-approved as a once weekly 30-to-90 second subcutaneous (SC) injection.

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

UnitedHealth Group

The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain.

The 3 Best Healthcare Stocks to Buy in June 2024

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?

Halozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its five-year financial outlook based on the new ENHANZE patent grant in Europe.

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.

News for Halozyme Therapeutics Stock (HALO)